Press release

PSE's gCOAS heralds breakthrough in computational oral absorption analysis

Formulation scientists can "bring new and better drugs to market earlier"

LONDON, 10 February 2015 --- Process Systems Enterprise (PSE), the Advanced Process Modelling company, today announced its new gCOAS® product for computational oral absorption at the Drug Development and Formulation Summit in Düsseldorf.

gCOAS, co-developed within the Systems-based Pharmaceutics (SbP) Alliance, is an analysis tool for a *priori* prediction of drug absorption in the human intestine as a function of product formulation parameters and ingestion conditions.

It provides formulation scientists with a tool that allows them to easily and quickly screen the performance of new formulations. The ultimate objective is to design a good dosage form in terms of amount of active pharmaceutical ingredient (API), particle size distribution of the API crystals, and other relevant attributes.

gCOAS aims to give unprecedented confidence in the accuracy of predictions of fractions absorbed using basic compound data, allowing more comprehensive early stage screening of promising candidate molecules and enabling the design of better formulations throughout the development lifecycle. These improved formulations reduce the risk to healthy volunteers and patients, as well as help reduce the number of trials, making it possible to bring new and better drugs to market earlier.

gCOAS is a key component of PSE's Systems-based Pharmaceutics vision, in which the formulation and manufacturing decisions are based on their effect on the efficacy of the drug. The ultimate goal of SbP is to identify the drug formulation that gives you the desired bioavailability while satisfying manufacturing constraints such as flowability and content uniformity as early as possible in the development cycle.

Editors

Contact: Kate Burness, +44-20-8563-0888, k.burness@psenterprise.com
'About' information: www.psenterprise.com/news/pr150210.html

About Process Systems Enterprise Ltd (PSE)

PSE (www.psenterprise.com) is the world's foremost provider of Advanced Process Modelling software and services to the process industries. Companies apply advanced process models to explore the process decision space rapidly and effectively, in order to reduce uncertainty and make better, faster and safer design and operating decisions.

PSE provides gPROMS family products built on its gPROMS$^®$ advanced modelling platform. These include the general-purpose gPROMS ModelBuilder environment and the domain-specific gSOLIDS$^®$, gCRYSTAL$^®$, gFUELCELL$^®$, gCOAS$^®$, gCCS$^®$, gFLARE$^®$ and gWATER$^®$ products. The company also provides expert Consulting services based on its tools.

Use of PSE's technology and services results in faster innovation, improved process and product designs, enhanced operations, reduced risk, more effective R&D and experimental campaigns and better capture and transfer of corporate knowledge across the organisation. Results are achieved with relatively low investment compared to alternative approaches, with rapid returns on investment.

PSE's global customer base of Fortune 500 process industry companies is served by operations in the UK, USA, Switzerland, Japan and Korea, and agencies in Abu Dhabi, China, Malaysia, Taiwan and Thailand. PSE is a spin-out of Imperial College London, and its software is used in over 200 universities around the world.

PSE is committed to defining, developing and driving the adoption of next-generation process modelling software and workflows. The company's own ability to innovate was recognised with the award of the prestigious Royal Academy of Engineering MacRobert Award for Engineering Innovation, the UK's highest engineering prize.